- $45.59m
- $71.25m
- $80.28m
Tela Bio Inc Reports Results For The Quarter Ended In December: Earnings Summary
Brief: TELA Bio Q4 Revenue USD 16.998 Million Vs. IBES Estimate USD 16.4 Million
Brief: Tela Bio Announces U.S. Commercial Launch Of Liquifix – The Only FDA-Approved Liquid Adhesive For Internal Use In Hernia Surgery
Brief: Tela Bio Announces Sale Of Distribution Rights For Wound Care Product To Mimedx
Tela Bio Inc Expected To Post A Loss Of 43 Cents A Share: Earnings Preview
Brief: TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Brief: TELA Bio Q3 Revenue USD 15.052 Million Vs. IBES Estimate USD 16.2 Million
Brief: First Light Asset Management, Llc Reports 10.33% Passive Stake In Tela Bio, Inc. As Of September 30
Brief: Tela Bio Announces U.S. Commercial Launch Of Ovitex® Prs Long-Term Resorbable For Plastic And Reconstructive Surgery
Brief: TELA Bio, Inc. Sees FY revenue USD 60-65 million
Tela Bio Inc Reports Results For The Quarter Ended In June: Earnings Summary
Tela Bio Inc Expected To Post A Loss Of 53 Cents A Share: Earnings Preview
Brief: Tela Bio Invests In Surgeon Training And Education With Upcoming Cadaver Lab
Tela Bio Inc Reports Results For The Quarter Ended In March: Earnings Summary
Brief: Tela Bio Reports First Quarter 2023 Financial Results
Tela Bio Inc Expected To Post A Loss Of 56 Cents A Share: Earnings Preview
U.S. STOCKS ON THE MOVE-CDW Corp, Bed Bath & Beyond, Elevance Health
U.S. STOCKS ON THE MOVE-United Airlines, Abbott Labs, Shift4 Payments